Requests that the FDA Require Adequate Cardiovascular Safety and All- Cause Mortality Data Be Submitted to FDA for Review Before Approving Roxadustat (FG-4592) for the Treatment of Anemia in Patients with Chronic Kidney Disease (CKD), and Require a Boxed Warning
🏛 Food and Drug Administration (FDA)FDA-2020-P-2193
Documents
0
Total comments
0
all analyzed
Comment status
Closed
Last activity
—
In this docket
Documents
Rules, notices, and supporting material — the primary rule pinned first.
No documents mirrored for this docket yet.